A new treatment for resistant hypertension using a long-lasting hormone.
Official title: A novel long-acting conjugate of the vasodilative hormone, human brain natriuretic peptide (hBNP), to treat resistant hypertension
Funded at Antlia Bioscience INC · NIH-10815642 · Data updated 2026-11-12
This study is testing a new long-lasting treatment using a hormone called hBNP to help people with stubborn high blood pressure that doesn't respond well to regular medications, making it easier for them to manage their condition.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Antlia Bioscience INC NIH-funded |
| Lab location | 1 site (Encinitas, United States) |
| Project start | September 19, 2024 |
| Project end | June 30, 2027 |
| Funding year | 2024 |
| Award (this year) | $999,998 |
| NIH project number | 1R44HL169016-01A1 |
| Project ID | NIH-10815642 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults aged 21 and older who have resistant hypertension and have not achieved adequate blood pressure control with existing medications.
✕Less likely to help
Patients who do not have hypertension or those whose condition is well-controlled with current treatments may not benefit from this research.
What this research studies
This research investigates a novel long-acting version of the hormone human brain natriuretic peptide (hBNP) to treat patients with resistant hypertension, a condition where blood pressure remains high despite treatment. The approach aims to enhance the effectiveness of hBNP, which naturally lowers blood pressure by promoting vasodilation and reducing fluid retention. By developing a formulation that allows for less frequent administration, the research seeks to improve patient adherence and outcomes. The study will involve monitoring the safety and efficacy of this new treatment in patients who struggle with traditional hypertension therapies.
Why it matters
Potential benefit: If successful, this research could provide a more effective and convenient treatment option for patients with resistant hypertension.
How similar studies have gone: While the use of hBNP has been previously tested for short-term effects, this long-acting formulation represents a novel approach that has not been extensively studied.
Where this research is happening
-
Antlia Bioscience INC
Encinitas, United States Active
Researchers
- Principal investigator: Johnson, Brian Laurence — Antlia Bioscience INC
- Study coordinator: Johnson, Brian Laurence
Related research
Other NIH-funded projects on the same topics.
-
HEARTS hypertension and diabetes care in Guatemala
This grant tests how well the HEARTS primary care model works in Guatemala to improve blood pressure and blood sugar control for patients.
-
Integrated Heart Health: A HEARTS-based approach to hypertension and diabetes in Guatemala
A study tests a team-based, stepwise care model to improve blood pressure and blood sugar control for people with both hypertension and diabetes in Guatemala.
-
Coaching and Navigation by Community Health Workers via Telehealth for High-Risk Hypertension
A program using telehealth and community health workers to help adults with severe hypertension connect to primary care and follow practical, heart-healthy lifestyle tips.
-
Community Health Worker–Led Hypertension Prevention and Control in Nepal
A community health worker–driven approach in Nepal aims to prevent and control high blood pressure among adults by bringing education and care directly to communities and homes.
-
Community health worker-led hypertension prevention and control in Nepal
A community health worker–led program in Nepal aims to help adults prevent and better control high blood pressure through home visits, education, and ongoing support.
-
Noninvasive portal pressure estimation using ultrasound-based subharmonic signals
A noninvasive ultrasound method to estimate portal vein pressure in adults with cirrhosis to help manage varices and ascites.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.